Iterum Therapeutics (ITRM) Scheduled to Post Earnings on Wednesday

Iterum Therapeutics (NASDAQ:ITRM) is set to announce its earnings results before the market opens on Wednesday, August 14th. Analysts expect the company to announce earnings of ($0.52) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Iterum Therapeutics (NASDAQ:ITRM) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.11. On average, analysts expect Iterum Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Iterum Therapeutics Price Performance

NASDAQ:ITRM opened at $1.13 on Tuesday. The stock has a market cap of $18.71 million, a PE ratio of -0.43 and a beta of 2.26. Iterum Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $2.50. The stock’s 50-day moving average is $1.24 and its two-hundred day moving average is $1.42.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Iterum Therapeutics in a research note on Friday, June 21st.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.